Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2930 + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
TQB2930 + oxaliplatin + capecitabine is an investigational combination therapy being evaluated for the treatment of HER2-positive unresectable locally advanced or metastatic colorectal cancer. TQB2930 is a biparatopic bispecific antibody developed by Chia Tai Tianqing that simultaneously targets two non-overlapping epitopes (ECD2 and ECD4) of the Human Epidermal Growth Factor Receptor 2 (HER2), leading to dual signal blockade and enhanced receptor internalization. Oxaliplatin is a platinum-based chemotherapy agent that forms DNA cross-links, inhibiting replication and transcription. Capecitabine is an oral prodrug of 5-fluorouracil that inhibits thymidylate synthase, interfering with DNA synthesis. This combination aims to provide synergistic anti-tumor activity by combining targeted HER2 inhibition with cytotoxic chemotherapy.
- Other names
- TQB2930 + CAPOXTQB2930 + XELOXTQB2930 plus oxaliplatin and capecitabineTQB-2930 plus oxaliplatin and capecitabineTQB 2930 plus oxaliplatin and capecitabine
02
Targets
TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on TQB2930 + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2930 + oxaliplatin + capecitabine.